Scinai Immunotherapeutics to Host Key Roundtable on Oral Bio-therapies at European Summit
On May 15, 2026, Scinai Immunotherapeutics Ltd., trading under the NASDAQ symbol SCNI, announced a pivotal moment for the company as it prepares to lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit in Amsterdam, Netherlands. This summit, an important event in the pharmaceutical calendar, will gather industry experts to discuss the future of dermatology therapeutics and the evolution of immunology.
The roundtable discussion will be entitled "Oral Therapies and the Future of Biologics: How Oral Peptides and Small Molecules Are Reshaping the Immunology Landscape." The session will feature insights from Amir Reichman, the Chief Executive Officer of Scinai, and Dr. Meital Portugal, the Director of Research and Development Operations. Bringing together a wealth of knowledge and experience, their leadership promises to facilitate an engaging dialogue about significant trends in the industry.
A central theme of the discussion will be whether advancements in oral peptide and small molecule therapies can complement existing biologic treatments, potentially reshaping treatment approaches in various disease contexts. With more emphasis on effectiveness, accessibility, and patient compliance, the conversations will delve into whether these new forms of therapy can compete with traditional injectable treatments.
Participants will explore various facets of this emerging question:
Dr. Amir Reichman emphasized, "We are experiencing a paradigm shift where efficacy is just one factor among many—durability of treatment, convenience for patients, stable responses, and access will also dictate the preferred choice in therapy. This dialogue underscores the importance of understanding where oral treatments can integrate with or even compete against traditional biologics."
Moreover, the roundtable will address the challenges associated with translating oral immunology therapies from research to clinical application. Topics will include pharmacokinetic variability, bioavailability issues, patient adherence challenges, and the durability of therapeutic responses, all crucial elements in the successful implementation of these innovative therapies.
Scinai's involvement reflects the company's commitment to pioneering novel approaches in immunology. With a portfolio that includes various advanced biologic formats and differentiated strategies targeting cytokines, Scinai is at the forefront of developing next-generation therapeutics.
The Dermatology Drug Development Summit draws biotechnology firms, pharmaceutical companies, researchers, clinicians, and leading figures in the industry, all aimed at innovating in the realm of dermatologic treatments and immune-mediated diseases. As Scinai leads discussions on oral therapies, the insights generated will undoubtedly contribute to shaping the future trajectory of immunology therapeutics.
About Scinai Immunotherapeutics:
Founded with a mission to spearhead advancements in immunology, Scinai Immunotherapeutics is advancing a robust pipeline of therapeutic candidates, developed in partnership with esteemed organizations such as the Max Planck Society and PinCell S.r.l. Additionally, Scinai operates Scinai Biopharma Services Ltd., a contract development and manufacturing organization, thereby providing essential services to biotechnology and pharmaceutical companies worldwide.
For further details about Scinai Immunotherapeutics and its innovative work in the field, visit www.scinai.com.
Contact Information:
Business Development: +972 8 930 2529
Investor Relations: Allele Capital Partners, +1 978 857 5075, [email protected]
Forward-Looking Statements:
This announcement contains forward-looking statements as defined by U.S. private securities regulations, reflecting Scinai’s expectations regarding its strategic initiatives and future market trends, which are subject to various risks and uncertainties. Scinai undertakes no obligation to revise these statements in light of future developments.
The roundtable discussion will be entitled "Oral Therapies and the Future of Biologics: How Oral Peptides and Small Molecules Are Reshaping the Immunology Landscape." The session will feature insights from Amir Reichman, the Chief Executive Officer of Scinai, and Dr. Meital Portugal, the Director of Research and Development Operations. Bringing together a wealth of knowledge and experience, their leadership promises to facilitate an engaging dialogue about significant trends in the industry.
A central theme of the discussion will be whether advancements in oral peptide and small molecule therapies can complement existing biologic treatments, potentially reshaping treatment approaches in various disease contexts. With more emphasis on effectiveness, accessibility, and patient compliance, the conversations will delve into whether these new forms of therapy can compete with traditional injectable treatments.
Participants will explore various facets of this emerging question:
- - Are there immunologic pathways where injectable biologics will always have the upper hand?
- - Can oral cytokine blockers demonstrate efficacy and durability comparable to biologics?
- - Which specific diseases or cytokine pathways might be impacted most by the introduction of oral therapies?
- - How will the route of administration influence portfolio development strategies in immunology?
- - In what ways can oral therapies affect physician confidence, treatment adherence, and payment dynamics?
Dr. Amir Reichman emphasized, "We are experiencing a paradigm shift where efficacy is just one factor among many—durability of treatment, convenience for patients, stable responses, and access will also dictate the preferred choice in therapy. This dialogue underscores the importance of understanding where oral treatments can integrate with or even compete against traditional biologics."
Moreover, the roundtable will address the challenges associated with translating oral immunology therapies from research to clinical application. Topics will include pharmacokinetic variability, bioavailability issues, patient adherence challenges, and the durability of therapeutic responses, all crucial elements in the successful implementation of these innovative therapies.
Scinai's involvement reflects the company's commitment to pioneering novel approaches in immunology. With a portfolio that includes various advanced biologic formats and differentiated strategies targeting cytokines, Scinai is at the forefront of developing next-generation therapeutics.
The Dermatology Drug Development Summit draws biotechnology firms, pharmaceutical companies, researchers, clinicians, and leading figures in the industry, all aimed at innovating in the realm of dermatologic treatments and immune-mediated diseases. As Scinai leads discussions on oral therapies, the insights generated will undoubtedly contribute to shaping the future trajectory of immunology therapeutics.
About Scinai Immunotherapeutics:
Founded with a mission to spearhead advancements in immunology, Scinai Immunotherapeutics is advancing a robust pipeline of therapeutic candidates, developed in partnership with esteemed organizations such as the Max Planck Society and PinCell S.r.l. Additionally, Scinai operates Scinai Biopharma Services Ltd., a contract development and manufacturing organization, thereby providing essential services to biotechnology and pharmaceutical companies worldwide.
For further details about Scinai Immunotherapeutics and its innovative work in the field, visit www.scinai.com.
Contact Information:
Business Development: +972 8 930 2529
Investor Relations: Allele Capital Partners, +1 978 857 5075, [email protected]
Forward-Looking Statements:
This announcement contains forward-looking statements as defined by U.S. private securities regulations, reflecting Scinai’s expectations regarding its strategic initiatives and future market trends, which are subject to various risks and uncertainties. Scinai undertakes no obligation to revise these statements in light of future developments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.